Skip to main content
SpringerLink
Log in
Book cover

Fachübergreifende Aspekte der Hämostaseologie V pp 89–102Cite as

Klinische Ergebnisse der Protein-C- und rhAPC-Substitution

  • Conference paper

  • 27 Accesses

Zusammenfassung

Klinische Manifestation eines schweren Protein-C-Mangels ist die Purpura fulminans. Bei angeborenem Protein-C-Mangel tritt diese in der Neonatalperiode auf, bei weniger ausgeprägtem Protein-C-Mangel eventuell bei Einleitung einer Kumarintherapie in Form einer Kumarinnekrose. Erworbene Protein-C-Mangelzustände oder Beeinträchtigungen des Protein-C-Systems können ebenfalls mit einer Purpura fulminans einhergehen. Diese wird insbesondere bei Meningokokkensepsis, aber auch bei anderen Infektionserkrankungen beobachtet. Entwickelt sich eine Purpura fulminans nach Abklingen des akuten Infektes, finden sich häufig Autoantikörper gegen Komponenten des Protein-C-Systems. Niedrige Protein-C-Spiegel werden auch bei Patienten mit septischen Zustandsbildern ohne Purpura fulminans gemessen und besitzen einen prädiktiven Wert hinsichtlich des klinischen Resultates. Für die Therapie stehen Protein-C-Konzentrat aus Humanplasma sowie rekombinantes aktiviertes Protein C zur Verfügung. Indikation zur Substitution von Protein C ist der manifeste Protein-C-Mangel mit Purpura fulminans oder anderen thrombotischen Manifestationen, oder auch Kumarinnekrose, bei ungestörter endogener Protein-C-Aktivierung. Weitere Indikation ist die Prophylaxe thrombotischer Ereignisse bei angeborenem schwerem Protein-C-Mangel. Bei Patienten mit septischen Zustandsbildern kann die Aktivierung von Protein C durch MikroZirkulationsstörungen, Ablösung von Thrombomodulin vom Endothel sowie durch mikrovaskuläre Thrombosen beeinträchtigt sein. Hier erscheint die Gabe von ex vivo aktiviertem Protein C sinnvoll. In einer multizentrischen, plazebokontrollierten Doppelblindstudie zeigte sich eine deutliche Senkung der 28-Tage-Mortalität bei Patienten mit schwerer Sepsis durch Therapie mit rekombinantem aktiviertem Protein C.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aiuto LT, Barone SR, Cohen PS, Boxer RA (1997) Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 25: 1079–1082

    Article  PubMed  CAS  Google Scholar 

  2. Alberio L, Lammle B, Esmon CT (2001) Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 32: 1338–1346

    Article  PubMed  CAS  Google Scholar 

  3. Al-Ismail S, Collins P, Najib R, James-Ellison M, O’Hagan M (1999) Postinfection purpura fulminans in a patient heterozygous for prothrombin G20210 A and acquired protein S resistance. Pediatr Hematol Oncol 16: 561–564

    Article  PubMed  CAS  Google Scholar 

  4. Auberger K (1992) Evaluation of a new protein C concentrate and comparison of protein C assays in a child with congenital protein C deficiency. Ann Hematol 64: 146–151

    Article  PubMed  CAS  Google Scholar 

  5. Bajzar L (2001) Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vase Biol 20: 2511 - 2518

    Article  Google Scholar 

  6. Bajzar L, Nesheim ME, Tracy PB (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88: 2093–2100

    PubMed  CAS  Google Scholar 

  7. Baliga V, Thwaites R, Tillyer ML, Minford A, Parapia L, Allgrove J (1995) Homozygous protein C deficiency-management with protein C concentrate. Eur J Pediatr 154: 534–538

    PubMed  CAS  Google Scholar 

  8. Bergmann F, Hoyer PF, D’Angelo SV, Mazzola G, Oesterich C, Bartheis M, D’Angelo A (1995) Severe autoimmune protein C deficiency in a boy with idiopathic purpura fulminans. Br J Haematol 89: 610–614

    Article  PubMed  CAS  Google Scholar 

  9. Bernard GR, Ely EW, Wright TJ et al. (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051–2059

    Article  PubMed  CAS  Google Scholar 

  10. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709

    Article  PubMed  CAS  Google Scholar 

  11. Busuttil DP, Hay CR, Lewis MA, Wynn RF (2000) Aggressive multiple modality therapy for varicella-associated purpura fulminans. Br J Haematol 110: 1012–1013

    Article  PubMed  CAS  Google Scholar 

  12. Carpenter CT, Kaiser AB (1997) Purpura fulminans in pneumococcal sepsis: case report and review. Scand J Infect Dis 29: 479–483

    Article  PubMed  CAS  Google Scholar 

  13. Clarke RC, Johnston JR, Mayne EE (2001) Meningococcal septicaemia: treatment with protein C concentrate. Intensive Care Med 26: 471–473

    Article  Google Scholar 

  14. Cnota JF, Barton LL, Rhee KH (1999) Purpura fulminans associated with streptococcus pneumoniae infection in a child. Pedriatr Emerg Care 15: 187–188

    Article  CAS  Google Scholar 

  15. Conlan MG, Bridges A, Williams E, Marlar R (1988) Familial type II protein C deficiency associated with warfarin-induced skin necrosis and bilateral adrenal hemorrhage. Am J Hematol 29: 226–229

    Article  PubMed  CAS  Google Scholar 

  16. Conway EM, Rosenberg RD (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 8: 5588–5592

    PubMed  CAS  Google Scholar 

  17. De Franzo AJ, Marasco P, Argenta LC (1995) Warfarin-induced necrosis of the skin. Ann Plast Surg 34: 203–208

    Article  Google Scholar 

  18. De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G (1993) Replacement therapy with a purified protein C concentrate during initiation of oral anti-coagulation in severe protein C congenital deficiency. Thromb Haemost 70: 247–249

    PubMed  Google Scholar 

  19. Dhainaut JF, Marin N, Mignon A, Vinsonneau C (2001) Hepatic response to sepsis: Interaction between coagulation and inflammatory processes. Crit Care Med 29: S42–S47

    Article  PubMed  CAS  Google Scholar 

  20. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G (1991) Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 325: 1565–1568

    Article  PubMed  CAS  Google Scholar 

  21. Ezer U, Misirlioglu ED, Colba V, Ogoz E, Kurt C (2001) Neonatal purpura fulminans due to homozygous protein C deficiency. Pediatr Hematol Oncol 18: 453–458

    Article  PubMed  CAS  Google Scholar 

  22. Faust SN, Levin M, Harrison OB et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408–416

    Article  PubMed  CAS  Google Scholar 

  23. Fijnvandraat K, Derkx B, Peters M et al. (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73: 15–20

    PubMed  CAS  Google Scholar 

  24. Galanakis A, Apokotou M, Alfadaki S, Gesouli E, Lapatsanis P (1999) Purpura fulminans complicating pneumococcal sepsis. Eur J Pediatr 158: 171

    Article  PubMed  CAS  Google Scholar 

  25. Gamba G, Montani N, Montecucco CM, Caporali R, Ascari E (1991) Purpura fulminans as clinical manifestation of atypical SLE with antiphospholipid antibodies: a case report. Haematologica 76: 426–428

    PubMed  CAS  Google Scholar 

  26. Herrera R, Hobar PC, Ginsburg CM (1994) Surgical intervention for the complications of meningococal-induced purpura fulminans. Pediatr Infect Dis J 13: 734–737

    Article  PubMed  CAS  Google Scholar 

  27. Huang DB, Price M, Pokorny J, Gabriel KR, Lynch R, Paletta CE (1999) Reconstructive surgery in children after meningococcal purpura fulminans. J Pediatr Surg 34: 595–601

    Article  PubMed  CAS  Google Scholar 

  28. Inbal A, Kenet G, Zivelin A et al. (1997) Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 77: 1086–1089

    PubMed  CAS  Google Scholar 

  29. Johansen K, Hansen ST (1992) Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis. Am J Surg 41: 24–31

    Google Scholar 

  30. Josephson C, Nuss R, Jacobson L, Hacker MR, Murphy J, Weinberg A, Manco-Johnson MJ (2001) The varicella-autoantibody syndrome. Pediatr Res 50: 345–352

    Article  PubMed  CAS  Google Scholar 

  31. Kemahli S, Alhenc-Gelas M, Gandrille S, Aiach M, Akar N, Cin S (1998) Homozygous protein C deficiency with a double variant His 202 to Tyr and Ala 346 to Thr. Blood Coagul Fibrinolysis 9: 351–354

    Article  PubMed  CAS  Google Scholar 

  32. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M (1999) Effect of factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 18: 893–896

    Article  PubMed  CAS  Google Scholar 

  33. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS (1995) Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 127: 355–363

    Article  PubMed  CAS  Google Scholar 

  34. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A (1993) Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103: 1536–1542

    CAS  Google Scholar 

  35. Manco-Johnson MJ, Abshire TC, Jacobson LJ, Marlar RA (1991) Severe neonatal protein C deficiency: prevalence and thrombotic risk. J Pediatr 119: 793–798

    Article  PubMed  CAS  Google Scholar 

  36. Manco-Johnson MJ, Nuss R, Key N et al. (1996) Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 128: 319–323

    Article  PubMed  CAS  Google Scholar 

  37. Marlar RA, Montgomery RR, Broekmans AW (1989) Diagnosis and treatment of homozygous protein C deficiency. Report of the working party on homozygous protein C deficiency of the subcommittee on protein C and protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 114: 528–534

    Google Scholar 

  38. Marlar RA, Sills RH, Groncy PK, Montgomery RR, Madden RM (1992) Protein C survival during replacement therapy in homozygous protein C deficiency. Am J Hematol 41: 24–31

    Article  PubMed  CAS  Google Scholar 

  39. Mesters RM, Heiterbrand J, Utterback BG et al. (2001) Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28: 2209–2216

    Google Scholar 

  40. Minford AM, Parapia LA, Stainforth C, Lee D (1996) Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol 93: 215–216

    Article  PubMed  CAS  Google Scholar 

  41. Mosnier LO, Meijers JC, Bouma BN (2001) Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 85: 5–11

    PubMed  CAS  Google Scholar 

  42. Muller FM, Ehrenthal W, Hafner G, Schranz D (1996) Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr 155: 20–25

    PubMed  CAS  Google Scholar 

  43. Nadel S, De Munter C, Britto J, Habibi P, Levin M (1998) Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 26: 971–972

    Article  PubMed  CAS  Google Scholar 

  44. Nguyen P, Reynaud J, Pouzol P, Munzer M, Richard O, Francois P (1994) Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 153: 646–649

    Article  PubMed  CAS  Google Scholar 

  45. Nolan J, Sinclair R (2001) Review of management of purpura fulminans and two case reports. Br J Anaesth 86: 581–586

    Article  PubMed  CAS  Google Scholar 

  46. Powars D, Larsen R, Johnson J et al. (1993) Epidemie meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 17: 254–261

    Article  PubMed  CAS  Google Scholar 

  47. Powars DR, Rogers ZR, Patch MJ, McGehee WG, Francis RB Jr (1987) Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S. N Engl J Med 317: 571–572

    Article  PubMed  CAS  Google Scholar 

  48. Rintala E, Kauppila M, Seppala OP, Voipio-Pulkki LM, Pettila V, Rasi V, Kotilainen P (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28: 2373–2378

    Article  PubMed  CAS  Google Scholar 

  49. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V (1998) Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26: 965–968

    Article  PubMed  CAS  Google Scholar 

  50. Rivard GE, David M, Farrell C, Schwarz HP (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 126: 646–652

    Article  PubMed  CAS  Google Scholar 

  51. Sanz-Rodriguez C, Gil-Fernandez J J, Zapater P et al. (1999) Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thromb Haemost 81: 887–890

    PubMed  CAS  Google Scholar 

  52. Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP (1993) Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 129: 753–756

    Article  PubMed  CAS  Google Scholar 

  53. Scully MF, Toh CH, Hoogendoorn H, Manuel RP, Nesheim ME, Solymoss S, Giles AR (1993) Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost 69: 448–453

    PubMed  CAS  Google Scholar 

  54. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W (1997) Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350: 1590–1593

    Article  PubMed  CAS  Google Scholar 

  55. Takano S, Kimura S, Odama S, Aoki N (1990) Plasma thrombomodulin in health and diseases. Blood 76: 2024–2029

    PubMed  CAS  Google Scholar 

  56. Tambyah PA, Kumarasinghe G, Chan HL, Lee KO (1997) Streptococcus suis infection complicated by purpura fulminans and rhabdomyolysis: case report and review. Clin Infect Dis 24: 710–712

    Article  PubMed  CAS  Google Scholar 

  57. Vary TC, Kimball SC (1992) Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 262: C445–C452

    PubMed  CAS  Google Scholar 

  58. Vukovich T, Auberger K, Weil J, Engelmann H, Knobl P, Hadorn HB (1988) Replacement therapy for a homozygous protein C deficiency state using a concentrate of human protein C and S. Br J Haematol 70: 435–440

    Article  PubMed  CAS  Google Scholar 

  59. Warren BL, Eid A, Singer P. (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286: 1869–1878

    Google Scholar 

  60. Watanabe R, Wada H, Sakakura M et al. (2001) Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. Am J Hematol 65: 35–40

    Article  Google Scholar 

  61. Wermes C, Bergmann F, Reller B, Sykora KW (1999) Severe protein C deficiency and aseptic osteonecrosis of the hip joint: a case report. Eur J Pediatr 158 (Suppl 3): S159–S161

    Article  PubMed  Google Scholar 

  62. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2001) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96: 3719–3724

    Google Scholar 

  63. Woods CR, Johnson CA (1998) Varicella purpura fulminans associated with heterozygosity for factor V Leiden and transient protein S deficiency. Pediatrics 102: 1208–1210

    Article  PubMed  CAS  Google Scholar 

  64. Yan SB, Heiterbrand JD, Hartman DL, Wright TJ, Bernard GR (2001) Low levels of protein c are associated with poor outcome in severe sepsis. Chest 120: 915–922

    Article  PubMed  CAS  Google Scholar 

  65. Zenz W, Bodo Z, Zobel G, Fanconi S, Rettenbacher A (1998) Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 26: 969–971

    Article  PubMed  CAS  Google Scholar 

  66. Zenz W, Muntean W, Zobel G, Grubbauer HM, Gallistl S (1995) Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator. Thromb Haemost 74: 802–803

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C.-E. Dempfle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Anästhesiologie, Universität Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland

    Eike Martin

  2. Medizinische Klinik I, Universität Heidelberg, Bergheimer Straße 58, 69115, Heidelberg, Deutschland

    Peter Nawroth

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Dempfle, CE. (2002). Klinische Ergebnisse der Protein-C- und rhAPC-Substitution. In: Martin, E., Nawroth, P. (eds) Fachübergreifende Aspekte der Hämostaseologie V. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93394-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93394-3_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-43350-7

  • Online ISBN: 978-3-642-93394-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation